GWS
HOWL icon

Glassman Wealth Services’s Werewolf Therapeutics HOWL Stock Holding History

Glassman Wealth Services’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-5
Closed -$15 – 2023
2023
Q2 		$15 Hold
5
– – ﹤0.01% 1900
2023
Q1 		$13 Hold
5
– – ﹤0.01% 1889
2022
Q4 		$10 Hold
5
– – ﹤0.01% 1906
2022
Q3 		$0 Hold
5
– – ﹤0.01% 1802
2022
Q2 		$0 Buy
+5
New +$23 ﹤0.01% 1811

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Glassman Wealth Services's HOWL Position: Q3 2023 in Review

Glassman Wealth Services sold out of Werewolf Therapeutics (HOWL) in Q3 2023, closing a stake of 5 shares — an estimated $15 sold.

Glassman Wealth Services first reported a position in HOWL in Q2 2022 and held it in 5 quarters. The position peaked at $15 in Q2 2023. 35 funds tracked by Wall St. Rank hold HOWL as of Q3 2023.

  • Glassman Wealth Services reported no remaining Werewolf Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Glassman Wealth Services sold 5 Werewolf Therapeutics shares in Q3 2023, an estimated $15.
  • Glassman Wealth Services first reported a position in Werewolf Therapeutics in Q2 2022 and held it in 5 quarters.
  • Glassman Wealth Services's Werewolf Therapeutics position peaked at $15 in Q2 2023.
  • 35 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q3 2023.

Based on Glassman Wealth Services's 13F filing for Q3 2023, filed 14 Nov 2023.